BI vs SYMBIOTEC: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. SYMBIOTEC PHARMALAB shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BI leads 0; SYMBIOTEC leads 1 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BI | SYMBIOTEC |
|---|---|---|
| Live Price | ₹91.66 | ₹1,036 |
| Day Change | -9.59% | -0.65% |
| Volume | 10.06 L | 2.72 L |
| 52-Week High | ₹111.51 | ₹1,193.7 |
| 52-Week Low | ₹51.62 | ₹934.2 |
| Distance from 52W High | -17.8% | -13.21% |
Valuation
| Metric | BI | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹245 Cr | ₹6,624 Cr |
| EPS | ₹0.44 | — |
| Book Value | ₹31.49 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BI | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -99.14% | — |
| Qtr Profit Growth | -93.05% | — |
Profitability & Leverage
| Metric | BI | SYMBIOTEC |
|---|---|---|
| ROE | -23.32% | — |
| ROCE | 7.37% | — |
| Net Margin | -2.36% | 0% |
| Operating Margin | 6.94% | — |
| Debt to Equity | 8.37x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BI | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 30.01% | 33.28% |
| FII Holding | 0.04% | 21.08% |
| DII Holding | 0% | 27.52% |
| Public Holding | 69.94% | 18.12% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BI and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.